Gracell Biotech launches $159m US IPO

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Asia

Gracell Biotech launches $159m US IPO

Jonathan Breen
January 05, 2021 08:30 am
Biotech_Adobe_575x375_Oct21
Female scientist researching samples in laboratory | Stevica Mrdja/Microgen - stock.adobe.com

Chinese clinical-stage company Gracell Biotechnologies has kicked off the roadshow for its Nasdaq listing, eyeing up to $158.9m in proceeds.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity IPOsHealth and BiotechEquityChinaAmericasCitiJefferies LLCAsiaGreater ChinaNortheast AsiaAsia PacificWells Fargo SecuritiesUnited StatesEmerging MarketsNorth AmericaSRI
JB
Jonathan Breen
Equities editor GlobalCapital Asia
Contact
Gift this article